---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125455"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:38:21.054080+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics Q3 net loss $11.9M; ENLIGHTEN 2 topline due Q2 2025

## Summary
- Cash & equivalents $51.6M as of Sep 30, 2024; runway into Q1 2026.
- R&D expenses fell to $5.9M from $12.4M YoY; G&A down to $3.9M from $5.0M.
- ENLIGHTEN 2 pivotal trial fully enrolled Oct 2024; topline results expected Q2 2025.
- ENLIGHTEN 1 extension study showed no product-related serious adverse events.
- Net loss improved to $11.9M vs $15.7M in Q3 2023.

## SEC filing metadata
- accession: 0000950170-24-125455
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017024125455/0000950170-24-125455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017024125455/lyra-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125455
- JSON: https://secwatch.observer/filing/0000950170-24-125455.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125455.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.